阿尔茨海默病和乙酰胆碱酯酶抑制剂:一项为期两年的纵向研究。

C Fuschillo, E Ascoli, G Franzese, F Campana, C Cello, M Galdi, S La Pia, C Cetrangolo
{"title":"阿尔茨海默病和乙酰胆碱酯酶抑制剂:一项为期两年的纵向研究。","authors":"C Fuschillo,&nbsp;E Ascoli,&nbsp;G Franzese,&nbsp;F Campana,&nbsp;C Cello,&nbsp;M Galdi,&nbsp;S La Pia,&nbsp;C Cetrangolo","doi":"10.1016/j.archger.2004.04.026","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and an urgent public health problem in many areas of the world. We present the results of the activity of an ad hoc ward, called \"Unità di Valutazione Alzheimer \" (UVA) (Unit of Evaluation for Alzheimer), along the first two years of the \"CRONOS\" project (CP). We evaluated the efficacy and safety of acetylcholinesterase inhibitor (AChE-I) agents in the treatment of mild to moderate AD and the population served by the UVA. Three hundred fifty-four patients referred to our ward for cognitive deficits. According to the CP criteria, 66 patients (42 women and 24 men, mean age 74.1 +/- 5.8 years) were enrolled in the study. Evaluation was carried out at baseline and after 3, 9, 15, and 21 months. Our results showed a positive impact of these drugs on patients with mild to moderate AD during the first nine months of treatment. After this period, we observed a progressive lowering of the mini mental state examination (MMSE) scores, with a global impairment of 0.9-1 .0 points per year. The adverse events were generally not troublesome. Our data strongly support the usefulness of UVA in the AD case ascertainment during the early phase of the disease.Moreover, the CP provided a general better knowledge about this important and devastating disease.</p>","PeriodicalId":77833,"journal":{"name":"Archives of gerontology and geriatrics. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.archger.2004.04.026","citationCount":"11","resultStr":"{\"title\":\"Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study.\",\"authors\":\"C Fuschillo,&nbsp;E Ascoli,&nbsp;G Franzese,&nbsp;F Campana,&nbsp;C Cello,&nbsp;M Galdi,&nbsp;S La Pia,&nbsp;C Cetrangolo\",\"doi\":\"10.1016/j.archger.2004.04.026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and an urgent public health problem in many areas of the world. We present the results of the activity of an ad hoc ward, called \\\"Unità di Valutazione Alzheimer \\\" (UVA) (Unit of Evaluation for Alzheimer), along the first two years of the \\\"CRONOS\\\" project (CP). We evaluated the efficacy and safety of acetylcholinesterase inhibitor (AChE-I) agents in the treatment of mild to moderate AD and the population served by the UVA. Three hundred fifty-four patients referred to our ward for cognitive deficits. According to the CP criteria, 66 patients (42 women and 24 men, mean age 74.1 +/- 5.8 years) were enrolled in the study. Evaluation was carried out at baseline and after 3, 9, 15, and 21 months. Our results showed a positive impact of these drugs on patients with mild to moderate AD during the first nine months of treatment. After this period, we observed a progressive lowering of the mini mental state examination (MMSE) scores, with a global impairment of 0.9-1 .0 points per year. The adverse events were generally not troublesome. Our data strongly support the usefulness of UVA in the AD case ascertainment during the early phase of the disease.Moreover, the CP provided a general better knowledge about this important and devastating disease.</p>\",\"PeriodicalId\":77833,\"journal\":{\"name\":\"Archives of gerontology and geriatrics. Supplement\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.archger.2004.04.026\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of gerontology and geriatrics. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.archger.2004.04.026\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of gerontology and geriatrics. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.archger.2004.04.026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

摘要

阿尔茨海默病(AD)是最常见的与年龄相关的神经退行性疾病,在世界许多地区都是一个紧迫的公共卫生问题。我们介绍了在“CRONOS”项目(CP)的头两年里,一个名为“阿尔茨海默病评估单位”(UVA)的特设病房的活动结果。我们评估了乙酰胆碱酯酶抑制剂(ache - 1)治疗轻中度AD和UVA服务人群的有效性和安全性。354个病人因为认知缺陷来我们病房就诊。根据CP标准,66例患者(42例女性,24例男性,平均年龄74.1±5.8岁)入组研究。在基线和3、9、15和21个月后进行评估。我们的研究结果显示,在治疗的前9个月,这些药物对轻度至中度AD患者有积极的影响。在这段时间之后,我们观察到迷你精神状态检查(MMSE)得分逐渐下降,每年整体损伤0.9- 1.0分。不良事件一般不麻烦。我们的数据强烈支持UVA在疾病早期确定AD病例的有用性。此外,CP提供了关于这一重要和毁灭性疾病的更全面的知识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study.

Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and an urgent public health problem in many areas of the world. We present the results of the activity of an ad hoc ward, called "Unità di Valutazione Alzheimer " (UVA) (Unit of Evaluation for Alzheimer), along the first two years of the "CRONOS" project (CP). We evaluated the efficacy and safety of acetylcholinesterase inhibitor (AChE-I) agents in the treatment of mild to moderate AD and the population served by the UVA. Three hundred fifty-four patients referred to our ward for cognitive deficits. According to the CP criteria, 66 patients (42 women and 24 men, mean age 74.1 +/- 5.8 years) were enrolled in the study. Evaluation was carried out at baseline and after 3, 9, 15, and 21 months. Our results showed a positive impact of these drugs on patients with mild to moderate AD during the first nine months of treatment. After this period, we observed a progressive lowering of the mini mental state examination (MMSE) scores, with a global impairment of 0.9-1 .0 points per year. The adverse events were generally not troublesome. Our data strongly support the usefulness of UVA in the AD case ascertainment during the early phase of the disease.Moreover, the CP provided a general better knowledge about this important and devastating disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信